AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00449-07v1
51/11/3908    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krupovic, M.
Right arrow Articles by Bamford, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krupovic, M.
Right arrow Articles by Bamford, D. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2007, p. 3908-3914, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00449-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Polymyxin B Induces Lysis of Marine Pseudoalteromonads{triangledown}

Mart Krupovic,1,2 Rimantas Daugelavicius,1,2 and Dennis H. Bamford1*

Department of Biological and Environmental Sciences and Institute of Biotechnology, Biocenter 2, P.O. Box 56 (Viikinkaari 5), 00014 University of Helsinki, Finland,1 Department of Biochemistry and Biophysics, Vilnius University, M. K. Ciurlionio 21, 03101 Vilnius, Lithuania2

Received 2 April 2007/ Returned for modification 30 April 2007/ Accepted 10 August 2007

Polymyxin B (PMB) is a cationic antibiotic that interacts with the envelopes of gram-negative bacterial cells. The therapeutic use of PMB was abandoned for a long time due to its undesirable side effects; however, the spread of resistance to currently used antibiotics has forced the reevaluation of PMB for clinical use. Previous studies have used enteric bacteria to examine the mode of PMB action, resulting in a somewhat limited understanding of this process. This study examined the effects of PMB on marine pseudoalteromonads and demonstrates that the frequently accepted view that "what is true for Escherichia coli is true for all bacteria" does not hold true. We show here that in contrast to the growth inhibition observed for enteric bacteria, PMB induces lysis of pseudoalteromonads, which is not prevented by high concentrations of divalent cations. Furthermore, we demonstrate that a high membrane voltage is required for the interaction of PMB with the cytoplasmic membranes of pseudoalteromonads, further elucidating the mechanisms by which PMB interacts with the cell envelopes of those gram-negative bacteria.


* Corresponding author. Mailing address: Viikki Biocenter, P.O. Box 56 (Viikinkaari 5), FIN-00014 University of Helsinki, Finland. Phone: 358 9 191 59100. Fax: 358 9 191 59098. E-mail: dennis.bamford{at}helsinki.fi

{triangledown} Published ahead of print on 20 August 2007.


Antimicrobial Agents and Chemotherapy, November 2007, p. 3908-3914, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00449-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.